West Pharmaceutical Services Inc

West Pharmaceutical Services stock has surged 38.1% since the end of March, far outpacing its industry's 9% gain and the S&P 500's 18.6% growth. The rally is supported by a sharp improvement in operating momentum, with the company delivering 13% organic revenue growth and 29% adjusted earnings per share growth in the second quarter. Management raised its 2026 outlook to 10-11% organic revenue growth, driven by strong demand for high-value proprietary products used in biologics and GLP-1 therapies. Proprietary Products grew 16% organically, Biologics jumped 29%, and HVP Components increased 18.4% to represent 49% of revenues. The company also benefits from Annex 1 upgrades, GLP-1 demand expansion, and a 29% organic surge in HVP Delivery Devices, while competitors Baxter, Becton Dickinson, and AptarGroup posted slower growth.

West Pharmaceutical Services reported second-quarter organic sales growth of 12.7% and adjusted earnings up 28.8% to $2.37 per share, driven by faster High-Value Product growth and wider margins. HVP Components generated $424.1 million in sales, or 49% of total company revenues, and grew 18.4% organically, supported by biologics, GLP-1 elastomers, and customer upgrades tied to Annex 1 requirements. Management expects Annex 1 and broader HVP conversion to add about 200 basis points to 2026 revenue growth, with just under 800 related projects in hand, up 50% from a year earlier. Second-quarter gross margin expanded 200 basis points year over year to 37.7%, and adjusted operating margin increased 230 basis points to 22.6%, helped by favorable HVP mix, pricing, and operating leverage. The company trades at 37.1 times forward 12-month earnings, versus 18.0 times for its Zacks sub-industry and 20.7 times for the S&P 500, a sizable relative premium though below its five-year median of 39.1 times. West Vantage grew just 0.8% organically in the second quarter due to cyber-related production downtime, and Standard Products grew only 0.7% organically, while the company ended June with $435.8 million in cash and cash equivalents against $202.9 million of total debt and repurchased 1.8 million shares for $454.3 million in the first half of 2026 under its $1 billion authorization.

West Pharmaceutical Services posted broad-based growth in the second quarter, driven by strong demand for high-value biologics packaging and proprietary delivery components. Organic revenue increased 15%, and management reinstated its favorable long-term growth outlook, citing continued demand from biologics and GLP-1 therapies. Conestoga Capital Advisors highlighted the stock as a performance contributor in its Q2 2026 investor letter, noting the quarter signaled a return to normalized growth rates after several years of post-COVID de-stocking. Shares of West Pharmaceutical Services gained 45.93% over the past 52 weeks and closed at $351.02 on August 5, 2026, with a market capitalization of $24.7 billion.

West Pharmaceutical Services reported higher second-quarter 2026 sales and earnings, raised its full-year 2026 net sales guidance to between US$3.345 billion and US$3.380 billion with organic growth now expected at 10% to 11%, up from a prior 7% to 9%, and completed US$454.28 million in share repurchases under its February 2026 buyback program. The company also issued third-quarter revenue guidance, highlighted momentum in higher-value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. The updated outlook reinforces the investment narrative centered on sustained demand for high-value components used in biologics, biosimilars, and GLP-1 therapies, though risks remain around potential demand shifts or pricing pressure.

West Pharmaceutical Services has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko, set to run over the next decade. Under the deal, West Pharmaceutical will distribute Daikyo products outside Japan, while Daikyo will distribute more West products within Japan, reinforcing their cross-border partnership in drug packaging technologies. The stock is trading around $328.2, up 18.7% year to date and 25.0% over the past year, though it has pulled back over the past 7 and 30 days. The extended cooperation provides a clearer framework for how products reach global markets and may influence capacity, product mix, and partnership opportunities in the coming years.

West Pharmaceutical Services reported second-quarter revenue of $872 million, up 13% organically, and adjusted earnings per share of $2.37, a 29% increase year-over-year. The company raised its full-year 2026 guidance, now expecting organic revenue growth of 10% to 11% and adjusted EPS between $8.85 and $9.05. Proprietary Products segment organic growth reached 16%, led by a 29% organic increase in the Biologics market group, while high-value product components revenue rose 18% organically to $424 million, now representing 49% of total company revenues. Gross margin improved 200 basis points to 37.7%, and adjusted operating margin expanded 230 basis points to 22.6%. The company repurchased 0.5 million shares for $157 million during the quarter and reported operating cash flow of $124 million against capital expenditures of $43 million.

West Pharmaceutical Services reported a second-quarter profit of $154.0 million, or $2.15 per share, up from $131.8 million, or $1.82 per share, a year earlier. Excluding items, adjusted earnings were $169.4 million, or $2.37 per share. Revenue rose 13.8% to $872.3 million from $766.5 million. The company issued guidance for the next quarter with earnings per share between $2.14 and $2.24 on revenue of $820 million to $835 million, and full-year earnings per share of $8.85 to $9.05 on revenue of $3.345 billion to $3.380 billion.

West Pharmaceutical Services is well positioned for growth, backed by strong demand for high-value products, expanding GLP-1 drug programs, and regulatory-driven Annex 1 conversions, though tariff impacts, destocking in generics, and execution challenges at constrained European facilities are concerns. Shares have gained 29.9% year to date against an industry decline of 0.7%, while the S&P 500 has risen 9.7%. The company, with a market capitalization of $25.41 billion, delivered a trailing four-quarter average earnings surprise of 19.37% and expects earnings to improve 13.9% over the next five years. Its high-value product components business delivered 23% organic growth in the first quarter, with more than two-thirds of the outperformance coming from non-GLP-1 products, and management raised full-year organic growth guidance to 7-9%. Annex 1-related projects increased 66% year over year, and the company expects Annex 1 and HVP conversion to contribute approximately 200 basis points to annual revenue growth in 2026, targeting at least 6 billion units for conversion. GLP-1-related HVP component sales represented 10% of total company revenues, and the biologics business grew 26% organically in the first quarter. The Zacks Consensus Estimate for 2026 earnings is $8.60 per share, implying an 18% gain, on revenues of $3.33 billion, indicating an 8.4% increase from the prior year.

West Pharmaceutical Services has sold the rights and facilities for its SmartDose 3.5 mL On Body Delivery System to AbbVie. The transaction shifts ownership of this specific large-volume wearable injector platform while West retains other SmartDose lines, including the 10 mL system, and continues to focus on higher-value drug delivery platforms such as GLP-1 related devices and larger-volume on-body systems. The deal is seen as a portfolio clean-up that reduces operational complexity and tightens the company's focus on areas with stronger growth potential. Investors may watch for how West backfills the divested capacity and whether the move improves margins and competitive positioning in injectable delivery.

West Pharmaceutical Services shares have risen 32.9% year to date in 2026, outperforming the industry's 30.3% decline and the S&P 500's 28.2% gain. The rally follows a strong first quarter where revenues grew 21% to $845 million and adjusted earnings per share surged 47%, prompting management to raise full-year guidance. Growth is being driven by accelerating demand for high-value product components used in GLP-1 obesity and diabetes therapies, which accounted for 10% of total company sales, as well as a 26% organic increase in biologics-related business. The company also reported a 66% year-over-year jump in projects tied to European Annex 1 sterile manufacturing regulations, expected to contribute approximately 200 basis points to 2026 revenues. While competition from Baxter International and Becton Dickinson remains intense, West Pharmaceutical's sharper focus on high-value pharmaceutical packaging and stronger margin expansion position it for continued momentum through the rest of the year.

West Pharmaceutical Services completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026. West will continue to develop and manufacture all other versions of SmartDose, including the SmartDose 10mL On-Body Delivery System and adaptive technology for larger volumes.

West Pharmaceutical Services reported a 21% revenue increase, driven by rising demand for its advanced drug containment and delivery solutions. The company also raised its full-year 2026 net sales guidance to between US$3.295 billion and US$3.350 billion. Analysts responded positively, noting that the company's proprietary and contract-manufactured products may reinforce its role in supporting complex injectable therapies. However, investors should remain aware of potential margin pressure from contract manufacturing transitions.

West Pharmaceutical Services stock may be about 6.9% undervalued based on a narrative fair value of $352.36, compared with its last closing price of $327.95. The bullish case rests on continued growth in GLP-1 drugs, which accounted for roughly 7% of total revenues in the first quarter, and a favorable mix shift toward higher-margin high-value products supported by approximately 340 Annex 1 projects. However, the stock's current price-to-earnings ratio of 42.7 times exceeds the peer average of 38.2 times and the global Life Sciences average of 34.3 times, pointing to valuation risk if sentiment cools. Key pressure points include high-value product capacity constraints and tariff or pricing risks that could weaken the outlook.